# 04_QA_REPORT.md

# Quality Assurance Report

## Identity

| Field | Value |
|---|---|
| QA ID | QA-PP-0221 |
| PP ID | PP-0221 |
| Title | Recurrence Detection |
| Version | 1.0.0 |
| Status | PASS |
| Production | GOLD |
| Source-First | PASS |
| Locked Decision Integrity | PASS |

---

# QA Scope

This report evaluates the PP-0221 four-artifact package against:

1. Approved + Locked PP-0221 Decision Batch.
2. CORE_WORKING_RULES.
3. FREEZE GOLD POPULATION PACKAGE SPECIFICATION.
4. DOCUMENT_ARCHITECTURE.
5. Approved PP Discussion depth/format reference.
6. Supplied project Source Materials.
7. Adjacent PP ownership and boundary logic.

The review is substantive across content, clinical, educational, governance, evidence-traceability, safety, Knowledge Graph and Gold-depth layers.

---

# Layer 1 — Content QA

| Criterion | Result | QA Note |
|---|---|---|
| Primary educational question | PASS | Explicitly asks how recurrence is recognized/evaluated. |
| Atomic scope | PASS | Detection/characterization, not treatment. |
| Recurrence definition | PASS | Included. |
| Recurrence vs progression | PASS | Explicitly separated. |
| Surveillance transition | PASS | PP-0220 → PP-0221 trigger is explicit. |
| Clinical triggers | PASS | Symptoms, examination, abnormal testing. |
| Imaging role | PASS | Included conceptually. |
| Endoscopy role | PASS | Included conceptually. |
| Biopsy/pathology role | PASS | Included with context-dependent wording. |
| Locoregional recurrence | PASS | Core. |
| Metastatic recurrence | PASS | Core classification. |
| Peritoneal recurrence | PASS | Core pattern with delegated detailed management. |
| Disease extent | PASS | Included. |
| Resectability/medical operability | PASS | Conceptual handoff. |
| Suspected vs established recurrence | PASS | Explicit. |
| Late recurrence | PASS | Included. |
| Evidence uncertainty | PASS | Preserved. |
| Patient explanation | PASS | Included. |
| Misconceptions | PASS | Included. |
| Patient questions | PASS | Included. |
| Knowledge Graph | PASS | Full upstream/downstream architecture. |

---

# Layer 2 — Clinical QA

| Criterion | Result | QA Note |
|---|---|---|
| Primary disease-specific source | PASS | NCCN Gastric Cancer v2.2026. |
| GAST-8 recurrence | PASS | Directly represented. |
| Locoregional vs metastatic | PASS | Correctly separated. |
| Resectable/operable distinction | PASS | Preserved as downstream management interface. |
| Unresectable/inoperable pathway | PASS | Routed downstream, not treated here. |
| GAST-10 peritoneal pathway | PASS | Correctly represented at diagnostic level. |
| CT role | PASS | Contextual, not technical. |
| FDG-PET/CT | PASS | Clinically indicated wording preserved. |
| Endoscopy | PASS | Diagnostic role supported by GAST-A. |
| Biopsy | PASS | Context-dependent; no universal rule invented. |
| Symptoms | PASS | Patient-facing nonspecificity preserved. |
| Recurrence timing | PASS | Population-level statistics correctly framed. |
| Late recurrence | PASS | Preserved. |
| No individual risk calculation | PASS | PASS. |
| No universal tumor-marker algorithm | PASS | Not invented. |
| No universal ctDNA/MRD algorithm | PASS | Not invented. |
| No treatment prescription | PASS | PASS. |
| No RECIST duplication | PASS | Delegated to PP-0218. |

---

# Layer 3 — Educational QA

| Criterion | Result | QA Note |
|---|---|---|
| Patient-facing clarity | PASS | Diagnostic sequence explained in plain language. |
| Clinical terminology | PASS | Technical terms are contextualized. |
| Reasoning depth | PASS | Includes trigger → reassessment → diagnostic evaluation → characterization → handoff. |
| Patient misconceptions | PASS | Ten misconceptions addressed. |
| Patient questions | PASS | Practical questions included. |
| Uncertainty | PASS | Explicitly communicated. |
| No false reassurance | PASS | Normal test is not treated as permanent exclusion. |
| No alarmism | PASS | Symptoms are not equated with recurrence. |
| Detection vs treatment | PASS | Strong boundary. |
| Detection vs surveillance | PASS | Strong boundary. |
| Detection vs progression | PASS | Strong boundary. |

---

# Layer 4 — Governance QA

| Criterion | Result | QA Note |
|---|---|---|
| Source-First | PASS | PP-specific clinical sources searched first. |
| PP identity | PASS | PP-0221 explicitly confirmed in registry. fileciteturn26file11 |
| Discussion template | PASS | PP-0112 Discussion example reviewed for format/depth. fileciteturn25file15 |
| Gold structure | PASS | Four required artifacts produced. |
| Scope lock | PASS | Artifacts follow approved Decision Batch. |
| No scope drift | PASS | No recurrent treatment algorithm. |
| Adjacent PP audit | PASS | PP-0217–PP-0230 interfaces checked. |
| Boundary structure | PASS | Core/Supporting/Explicitly Excluded/Delegated-to PP. |
| Evidence traceability | PASS | High-impact claims mapped to source set. |
| Knowledge Graph | PASS | Upstream/current/downstream structure present. |
| QA depth | PASS | Multi-layer substantive QA included. |
| Stop condition | PASS | Production ends after QA. |

---

# Clinical Safety Review

## Safety 1 — Symptoms are not diagnoses

The package explicitly states that symptoms can have multiple causes.

**PASS**

## Safety 2 — Suspicious imaging is not automatically recurrence

The package preserves diagnostic uncertainty.

**PASS**

## Safety 3 — Biopsy is not universally mandatory

The package avoids a universal biopsy rule.

**PASS**

## Safety 4 — No individualized recurrence diagnosis

The package provides education only.

**PASS**

## Safety 5 — No individualized recurrence probability

Population recurrence timing is not converted into patient risk.

**PASS**

## Safety 6 — No individualized treatment

Treatment is delegated to PP-0222 and downstream packages.

**PASS**

## Safety 7 — No universal tumor-marker algorithm

No unsupported threshold or rule is introduced.

**PASS**

## Safety 8 — No universal ctDNA/MRD algorithm

The evidence gap is explicitly preserved.

**PASS**

---

# Adjacent PP Overlap Audit

## PP-0217 — Response Assessment

**Boundary**

Treatment response/progression during active therapy.

PP-0221:

Recurrence after prior treatment.

**Result: PASS**

---

## PP-0218 — RECIST-based Assessment

**Boundary**

RECIST standardizes response/progression assessment.

PP-0221 does not reproduce RECIST.

**Result: PASS**

---

## PP-0219 — Post-treatment Imaging

**Boundary**

Post-treatment imaging as disease-status assessment.

PP-0221:

Suspicious imaging findings as part of recurrence evaluation.

**Result: PASS**

---

## PP-0220 — Surveillance

**Boundary**

Routine longitudinal surveillance.

PP-0221:

Evaluation once concern for recurrence arises.

**Result: PASS**

---

## PP-0222 — Management of Recurrent Gastric Cancer

**Boundary**

PP-0221 detects/characterizes.

PP-0222 manages.

**Critical boundary: PASS**

---

## PP-0223 — Metastatic Gastric Cancer

Metastatic disease is classified here but detailed metastatic disease management is delegated.

**PASS**

---

## PP-0224 — Peritoneal Carcinomatosis

Peritoneal recurrence is recognized; detailed disease-state management delegated.

**PASS**

---

## PP-0225 — Peritoneal Carcinoma as Only Disease

Dedicated disease-state package remains downstream.

**PASS**

---

## PP-0226 — HIPEC

No HIPEC treatment algorithm in PP-0221.

**PASS**

---

## PP-0227/0228 — Palliative / Best Supportive Care

Only downstream transition is acknowledged.

**PASS**

---

## PP-0229/0230 — Survivorship / Long-term Follow-up

No survivorship or long-term-care takeover.

**PASS**

---

# Evidence Traceability Audit

| Domain | Primary Trace | Result |
|---|---|---|
| Recurrence pathway | NCCN GAST-8 | PASS |
| Locoregional recurrence | NCCN GAST-8 | PASS |
| Metastatic disease | NCCN GAST-8 | PASS |
| Resectability | NCCN GAST-8 | PASS |
| Peritoneal work-up | NCCN GAST-10 | PASS |
| Endoscopy | NCCN GAST-A | PASS |
| Recurrence timing | NCCN GAST-H | PASS |
| Symptom context | ACS | PASS |
| Treatment boundary | NCCN GAST-9 | PASS |
| Survivorship boundary | NCCN GAST-I | PASS |

**Evidence Traceability: PASS**

---

# Numerical Evidence Audit

| Numerical claim | Result |
|---|---|
| 70–80% recurrence within 2 years | PASS |
| ~90% recurrence by 5 years | PASS |

The figures are explicitly presented as population-level NCCN evidence summaries and not as individual patient risk.

No unsupported numerical diagnostic thresholds were introduced.

**PASS**

---

# Knowledge Graph Audit

| Relationship | Result |
|---|---|
| Response assessment upstream | PASS |
| RECIST upstream | PASS |
| Post-treatment imaging upstream | PASS |
| Surveillance upstream | PASS |
| Recurrence detection current node | PASS |
| Recurrent-disease management downstream | PASS |
| Metastatic disease downstream | PASS |
| Peritoneal disease downstream | PASS |
| HIPEC downstream | PASS |
| Palliative/supportive care downstream | PASS |
| Survivorship/long-term follow-up boundary | PASS |

**Knowledge Graph: PASS**

---

# Evidence Gap Audit

| Potential Overclaim | Status |
|---|---|
| Universal biopsy | Explicitly rejected |
| Tumor-marker-only recurrence diagnosis | Explicitly excluded |
| Universal ctDNA/MRD recurrence algorithm | Explicitly excluded |
| One test always proves recurrence | Explicitly rejected |
| Individual recurrence probability | Explicitly excluded |
| Five years = zero recurrence risk | Explicitly rejected |
| Imaging = automatic recurrence diagnosis | Explicitly rejected |

**Evidence Gap Integrity: PASS**

---

# Gold Depth Integrity Review

## Absolute Rule

The four artifacts must not be shortened, compacted, summarized or made shallower than the approved Gold references.

Depth is relative to the Gold reference standard, not a fixed line count.

## 01_CKO

Required depth domains present:

- identity;
- objectives;
- clinical journey;
- scope;
- detailed knowledge blocks;
- clinical importance;
- patient explanation;
- evidence maturity;
- misconceptions;
- patient questions;
- key messages;
- safety;
- Knowledge Graph;
- boundary;
- revision history.

**PASS**

## 02_KNOWLEDGE_PASSPORT

Required depth domains present:

- classification;
- clinical intent;
- ownership;
- runtime retrieval;
- retrieval exclusions;
- knowledge units;
- evidence hierarchy;
- Knowledge Graph;
- boundary map;
- safety rules;
- traceability;
- version control.

**PASS**

## 03_PRIMARY_EVIDENCE_PACKAGE

Required depth domains present:

- clinical question;
- source hierarchy;
- evidence matrix;
- detailed evidence notes;
- claim maturity;
- evidence gaps;
- patient translation;
- consistency review;
- source traceability;
- boundary verification;
- update triggers;
- final evidence status.

**PASS**

## 04_QA_REPORT

Required depth domains present:

- content QA;
- clinical QA;
- educational QA;
- governance QA;
- safety;
- adjacent PP overlap;
- evidence traceability;
- numerical audit;
- Knowledge Graph;
- evidence-gap audit;
- Gold-depth audit;
- cross-artifact consistency;
- package integrity;
- final QA status.

**PASS**

---

# Cross-artifact Consistency

| Domain | CKO | KP | EP | QA | Result |
|---|---|---|---|---|---|
| Primary question | ✓ | ✓ | ✓ | ✓ | PASS |
| Recurrence scope | ✓ | ✓ | ✓ | ✓ | PASS |
| Surveillance boundary | ✓ | ✓ | ✓ | ✓ | PASS |
| Response/RECIST boundary | ✓ | ✓ | ✓ | ✓ | PASS |
| Imaging boundary | ✓ | ✓ | ✓ | ✓ | PASS |
| Biopsy/pathology boundary | ✓ | ✓ | ✓ | ✓ | PASS |
| Locoregional recurrence | ✓ | ✓ | ✓ | ✓ | PASS |
| Metastatic recurrence | ✓ | ✓ | ✓ | ✓ | PASS |
| Peritoneal recurrence | ✓ | ✓ | ✓ | ✓ | PASS |
| Management handoff | ✓ | ✓ | ✓ | ✓ | PASS |
| Evidence gaps | ✓ | ✓ | ✓ | ✓ | PASS |
| Knowledge Graph | ✓ | ✓ | ✓ | ✓ | PASS |
| Boundary | ✓ | ✓ | ✓ | ✓ | PASS |

**Cross-artifact consistency: PASS**

---

# Package Integrity

Expected structure:

```text
PP-0221_Recurrence_Detection_GOLD_v1.0.0/
├── 01_CKO.md
├── 02_KNOWLEDGE_PASSPORT.md
├── 03_PRIMARY_EVIDENCE_PACKAGE.md
└── 04_QA_REPORT.md
```

All four required artifacts are present.

No additional artifact was introduced.

No required artifact is missing.

**Package Integrity: PASS**

---

# Final QA Decision

## Content QA

**PASS**

## Clinical QA

**PASS**

## Educational QA

**PASS**

## Governance QA

**PASS**

## Clinical Safety

**PASS**

## Adjacent PP Overlap

**PASS**

## Evidence Traceability

**PASS**

## Numerical Evidence

**PASS**

## Knowledge Graph

**PASS**

## Evidence Gap Integrity

**PASS**

## Gold Depth Integrity

**PASS**

## Cross-artifact Consistency

**PASS**

## Package Integrity

**PASS**

---

# Final QA Status

**PASS — GOLD — READY FOR INTEGRATION**

---

# Revision History

| Version | Date | Change |
|---|---|---|
| 1.0.0 | 2026-08-09 | Initial Gold QA following Approved + Locked PP-0221 Decision Batch. |
